Peptron, Inc.

Equities

A087010

KR7087010005

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-07 pm EDT			5-day change	1st Jan Change
30,750 ^KRW	+1.15%		+6.03%	-23.60%

2023	Invex Therapeutics, Peptron End Collaboration, Manufacturing Deal	MT
2023	Tranche Update on Peptron, Inc.'s Equity Buyback Plan announced on April 5, 2023.	CI

Tranche Update on Peptron, Inc.'s Equity Buyback Plan announced on April 5, 2023.

October 04, 2023 at 03:21 am EDT

From July 1, 2023 to September 30, 2023, the company has repurchased 20,242 shares, representing 0.1% for KRW 446.17 million. With this, the company has completed the repurchase of 73,961 shares, representing 0.36% for KRW 891.08 million under the buyback announced on April 5, 2023.

Latest news about Peptron, Inc.

Invex Therapeutics, Peptron End Collaboration, Manufacturing Deal	Dec. 21	MT
Tranche Update on Peptron, Inc.'s Equity Buyback Plan announced on April 5, 2023.	23-10-04	CI
Tranche Update on Peptron, Inc.'s Equity Buyback Plan announced on April 5, 2023.	23-10-04	CI
Peptron, Inc.'s Equity Buyback announced on April 5, 2023, has expired with 73,961 shares, representing 0.36% for KRW 891.08 million.	23-10-03	CI
Tranche Update on Peptron, Inc.'s Equity Buyback Plan announced on April 5, 2023.	23-07-07	CI
Peptron, Inc. announces an Equity Buyback for KRW 3,000 million worth of its shares.	23-04-05	CI
Peptron, Inc. authorizes a Buyback Plan.	23-04-04	CI
Peptron, Inc. Establishes Bioequivalence of PT105	22-11-27	CI
Invex Therapeutics Ltd Announces the Signing of a Long Term Collaboration and Manufacturing Agreement with Peptron, Inc	21-09-26	CI
Qilu Pharmaceutical and Peptron Sign License Agreement for Anti-MUC1 ADC	21-04-16	CI
Peptron, Inc. Announces Published Data Showing a New Sustained-Release Exendin-4 Formulation Prevents Neurodegeneration in a Parkinson's Disease Model	18-07-16	CI
Peptron, Inc. announced that it has received $24 million in funding	18-04-22	CI
Peptron, Inc. announced that it has received KRW 25.5 billion in funding from Industrial Bank of Korea	18-01-30	CI
Peptron, Inc. announced that it expects to receive KRW 25.5 billion in funding from Industrial Bank of Korea	18-01-28	CI
Peptron, Inc. announced that it has received funding from E&Investment,Inc.	16-04-24	CI
Peptron, Inc. announced that it has received KRW 2 billion in funding from UNO & COMPANY Ltd.	16-04-24	CI
Peptron, Inc. announced that it expects to receive KRW 2 billion in funding from UNO & COMPANY Ltd.	16-04-19	CI
Peptron, Inc.(KOSDAQ:A087010) added to Russell Global Index	15-10-01	CI
Peptron, Inc.(KOSDAQ:A087010) added to S&P Global BMI Index	15-09-21	CI
Peptron, Inc. has completed an IPO in the amount of KRW 13.04 billion.	15-07-17	CI
Peptron, Inc. has filed an IPO.	14-09-04	CI
UNO&COMPANY Ltd. acquired 3.66% stake in Peptron, Inc. for approximately KRW 1 billion.	14-02-09	CI

Chart Peptron, Inc.

Duration

Period

More charts

Company Profile

Peptron, Inc. is a Korea-based company principally engaged in the development, manufacture and distribution of sustained-release medications. The Company mainly produces peptides as drug materials mainly for prostate cancer, hyperpituitarism, diabetes and neurodegenerative disorders. The Company also provides peptide synthesis services. The Company manufactures raw material medicines and some functional cosmetics. The Company distributes its products within domestic market and to overseas markets.

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PEPTRON, INC.	-23.60%	462M
VERTEX PHARMACEUTICALS INCORPORATED	+2.93%	106B
ARGENX SE	+7.02%	23.47B
BIONTECH SE	-14.60%	21.9B
GENMAB A/S	-7.05%	18.77B
WUXI APPTEC CO., LTD.	-38.55%	17.85B
BEIGENE, LTD.	-8.83%	16.78B
NEUROCRINE BIOSCIENCES, INC.	+5.51%	14.41B
SAREPTA THERAPEUTICS, INC.	+37.49%	12.86B
VIKING THERAPEUTICS, INC.	+329.39%	8.78B

Bio Therapeutic Drugs